Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Towards an optimum strategy in rheumatoid arthritis.

Emery P, Buch MH.

Lancet. 2012 May 5;379(9827):1682-4. doi: 10.1016/S0140-6736(12)60164-0. Epub 2012 Mar 29. No abstract available.

PMID:
22464342
2.

Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.

Ornetti P, Solau E, Gaudin P, Sibilia J, Berthelot JM, Puechal X, Tavernier C, Maillefert JF; Club Rhumatismes et Inflammation from the French Society of Rheumatology.

Ann Rheum Dis. 2005 Sep;64(9):1379-80. No abstract available.

3.

[Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].

D'Alessandro G, Bianco MR, Politis S, Ferrandina C, Rossi G, Altomare E.

Reumatismo. 2006 Jan-Mar;58(1):59-61. Italian.

4.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P.

Lancet. 1999 Dec 4;354(9194):1932-9.

PMID:
10622295
5.

Infliximab treatment of rheumatoid arthritis.

Maini SR.

Rheum Dis Clin North Am. 2004 May;30(2):329-47, vii. Review.

PMID:
15172044
6.

Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.

Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C.

Arthritis Rheum. 2007 Dec;56(12):4226-7. No abstract available.

7.

Adalimumab for rheumatoid arthritis?

Ebell M, Kripke C.

Am Fam Physician. 2006 Feb 1;73(3):435-6. Review. No abstract available.

8.

[Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis].

Imagama T, Taguchi T.

Nihon Rinsho. 2013 Jul;71(7):1209-13. Review. Japanese.

PMID:
23961668
9.

Polymyositis associated with infliximab treatment for rheumatoid arthritis.

Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y.

Mod Rheumatol. 2006;16(6):410-1. Epub 2006 Dec 20. No abstract available.

PMID:
17165006
10.

[New therapies in rheumatoid arthritis. Stopping joint deterioration].

Rautenstrauch J.

MMW Fortschr Med. 2000 Jan 20;142(3):4-8. German. No abstract available.

PMID:
10726453
11.

New drugs for rheumatoid arthritis.

Messori A, Santarlasci B, Vaiani M.

N Engl J Med. 2004 Aug 26;351(9):937-8. No abstract available.

12.

Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?

Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V.

J Rheumatol. 2006 Feb;33(2):433; author reply 433-4. No abstract available.

PMID:
16465676
13.

Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis.

Wakefield RJ, Freeston JE, Hensor EM, Bryer D, Quinn MA, Emery P.

Arthritis Rheum. 2007 Dec 15;57(8):1564-7. No abstract available.

14.

Treatment of rheumatoid arthritis: we are getting there.

Yazici Y.

Lancet. 2009 Jul 18;374(9685):178-80. doi: 10.1016/S0140-6736(09)60792-3. Epub 2009 Jun 26. No abstract available.

PMID:
19560809
15.

Rheumatoid arthritis.

Burchini G, Orsi C.

N Engl J Med. 2004 Sep 23;351(13):1360-1; author reply 1360-1. No abstract available.

16.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, Zickert A, Theander J, Thörner A, Hellström H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M, Bratt J.

Lancet. 2009 Aug 8;374(9688):459-66. doi: 10.1016/S0140-6736(09)60944-2.

PMID:
19665644
17.

[Infliximab for therapy of rheumatoid arthritis].

Amano K.

Nihon Rinsho. 2005 Jan;63 Suppl 1:517-20. Review. Japanese. No abstract available.

PMID:
15799410
18.

Infliximab: a review of its use in the management of rheumatoid arthritis.

Markham A, Lamb HM.

Drugs. 2000 Jun;59(6):1341-59. Review.

PMID:
10882166
19.

When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

Smolen JS, Weinblatt ME.

Ann Rheum Dis. 2008 Nov;67(11):1497-8. doi: 10.1136/ard.2008.098111. No abstract available.

PMID:
18854512
20.

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.

Delabaye I, De Keyser F; REMITRACT study group.

Arthritis Res Ther. 2010;12(3):R121. doi: 10.1186/ar3058. Epub 2010 Jun 22.

Supplemental Content

Support Center